PolyNovo (ASX:PNV) said its NovoSorb BTM and NovoSorb MTX devices available for sale in the US are only subject to the 10% tariff imposed on exports to the US and will not be affected by the new tariffs on pharmaceutical products, according to a Tuesday filing with the Australian bourse.
The medical technology firm also said it has about a year's worth of inventory within the US, with the capacity to increase levels.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.